Scholarlink

Purpose of Review <p>Hypertriglyceridemia is known to be associated with the development of atherosclerotic cardiovascular disease (ASCVD). Severe hypertriglyceridemia (SHTG), defined as serum triglycerides ≥ 500&#xa0;mg/dL, carries the additional risk of acute pancreatitis. This review will discuss an approach to evaluation and management of clinical challenges in SHTG.</p> Recent Findings <p>APOC3 inhibition is a novel target in the treatment of SHTG. Several RNA-based APO3 inhibitors have shown promising results, including in patients with Familial Chylomicronemia Syndrome (FCS).</p> Summary <p>We will explore available triglyceride-lowering medications, inpatient management of patients with acute pancreatitis secondary to SHTG, special considerations during pregnancy, current dietary recommendations, and emerging therapeutic options for SHTG. Additionally, we will highlight the importance of distinguishing Multifactorial Chylomicronemia Syndrome (MCS) from FCS, discuss their genetic bases, and examine the differing approaches to diagnosis and management of these disorders.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnosis, Evaluation, and Management of Severe Hypertriglyceridemia

  • 期刊论文

  • 发表日期：

    2025年1月21日

查看全文
  • Amrita Krishnamurthy,
  • Edwin Homan,
  • Samuel M. Kim

摘要

Purpose of Review

Hypertriglyceridemia is known to be associated with the development of atherosclerotic cardiovascular disease (ASCVD). Severe hypertriglyceridemia (SHTG), defined as serum triglycerides ≥ 500 mg/dL, carries the additional risk of acute pancreatitis. This review will discuss an approach to evaluation and management of clinical challenges in SHTG.

Recent Findings

APOC3 inhibition is a novel target in the treatment of SHTG. Several RNA-based APO3 inhibitors have shown promising results, including in patients with Familial Chylomicronemia Syndrome (FCS).

Summary

We will explore available triglyceride-lowering medications, inpatient management of patients with acute pancreatitis secondary to SHTG, special considerations during pregnancy, current dietary recommendations, and emerging therapeutic options for SHTG. Additionally, we will highlight the importance of distinguishing Multifactorial Chylomicronemia Syndrome (MCS) from FCS, discuss their genetic bases, and examine the differing approaches to diagnosis and management of these disorders.